超中心、中心和旁纵隔肺肿瘤立体定向体部放疗后的肿瘤控制与毒性
本研究回顾了2009年9月至2017年7月接受立体定向体部放疗(SBRT)的68例中央型肺肿瘤患者(共69个肿瘤,包括14个超中心、15个旁纵隔和39个中心肿瘤),比较其毒性、疾病控制和生存率。结果显示三组2年局部控制率和总生存率相似,但超中心肿瘤的2级及以上毒性风险增加。
要点
- 超中心、中心和旁纵隔肺肿瘤SBRT后2年局部控制率和总生存率相似。
- 超中心肿瘤2年2级及以上毒性发生率为57.6%,高于中心的14.2%和旁纵隔的7.1%。
- 一例超中心肿瘤患者发生5级呼吸衰竭。
核心结论
- 超中心、中心和旁纵隔肺肿瘤SBRT后的肿瘤学结局相似,主要采用5次分割方案时2年局部控制率超过85%。
- 在本患者队列中,超中心肺肿瘤与毒性风险增加相关。
- 需要额外研究以尽量减少超中心肿瘤的毒性。
研究设计与样本
- 回顾性分析了2009年9月至2017年7月间接受SBRT的中央型肺肿瘤患者的记录。
- 共识别68例患者、69个中央型肺肿瘤,包括14个超中心、15个旁纵隔和39个中心肿瘤。
- 53例为早期肺癌,15例为肺转移。
- 处方剂量为40 Gy至60 Gy,分3至8次。
- 大多数患者采用5次分割(83%),其次为8次分割(10%)。
主要发现
- 超中心、中心和旁纵隔肿瘤的2年局部控制率分别为89%、85%和93%(P = .72)。
- 超中心、中心和旁纵隔肿瘤的2年总生存率分别为76%、73%和72%(P = .75)。
- 超中心、中心和旁纵隔肿瘤的2年2级及以上毒性发生率分别为57.6%、14.2%和7.1%(P = .007)。
- 一例超中心肿瘤患者发生5级呼吸衰竭。
关键数值与推荐
- 中心肿瘤定义为距离近端支气管树(PBT)2 cm以内。
- 超中心肿瘤定义为计划靶体积触及PBT或食管。
- 旁纵隔肿瘤定义为触及纵隔胸膜。
- 毒性采用不良事件通用术语标准4.03版评分。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要额外研究以尽量减少超中心肿瘤的毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Increased rates of toxicity have been described after stereotactic body radiation therapy (SBRT) for central lung tumors within 2 cm of the proximal bronchial tree (PBT). Recent studies have defined a new class of ultracentral tumors. We report our experience treating ultracentral, central, and paramediastinal tumors with SBRT and compare toxicity, disease control, and survival rates. METHODS AND MATERIALS: We reviewed the records of patients with central lung tumors treated with SBRT between September 2009 and July 2017. Tumors were classified as central if within 2 cm of the PBT, ultracentral if the planning target volume touched the PBT or esophagus, and paramediastinal if touching mediastinal pleura. Actuarial rates of grades 2+ and 3+ toxicity, local control (LC), and overall survival were assessed using the Kaplan-Meier method and compared using a log-rank test. Toxicity was scored with the Common Terminology Criteria for Adverse Events, version 4.03. RESULTS: We identified 68 patients with 69 central lung tumors, including 14 ultracentral, 15 paramediastinal, and 39 central tumors. Fifty-three patients were treated for early stage lung cancer and 15 for lung metastases. The prescribed dose ranged from 40 Gy to 60 Gy over 3 to 8 fractions. Most patients were treated using 5 fractions (83%), followed by 8 fractions (10%). Median follow-up was 19.7 months (range, 3.3-78.3 months). The 2-year estimates of LC (89%, 85%, and 93%, respectively; P = .72) and overall survival (76%, 73%, and 72%, respectively; P = .75) for ultracentral, central, and paramediastinal tumors were similar. Ultracentral tumors had an increased risk of grade 2+ toxicity (57.6% vs 14.2% vs 7.1%; P = .007) at 2 years. One patient with an ultracentral tumor developed grade 5 respiratory failure. CONCLUSIONS: The oncologic outcomes after SBRT for ultracentral, central, and paramediastinal lung tumors were similar, with LC exceeding 85% at 2 years using predominantly 5-fraction schedules. Ultracentral lung tumors were associated with an increased risk of toxicity in our patient cohort. Additional studies are needed to minimize toxicity for ultracentral tumors.
引用
- Nguyen KNB, Hause DJ, Novak J, et al. Tumor Control and Toxicity after SBRT for Ultracentral, Central, and Paramediastinal Lung Tumors. Pract Radiat Oncol. 2018. PMID: 30496842. doi:10.1016/j.prro.2018.11.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。